Sun Pharma receives USFDA approval for Cerebyx

New Delhi, Mar 19 (UNI) Sun Pharmaceutical Industries Ltd today said it has received the US Food and Drug Administration approval for the Abbreviated New Drug Application (ANDA) to market a generic version of Parke Davis's Cerebyx, fosphenytoin sodium injection.

Fosphenytoin sodium Injection has annual sales of about 15 million dollars in the US, a company statemet said.

Fosphenytoin sodium is used for the control of generalised convulsive status epilepticus as well as for prevention and treatment of seizures occurring during neurosurgery.

UNI SR MP KN1730